{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:11:50Z","timestamp":1788412310630,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.ijcard.2018.03.107","type":"journal-article","created":{"date-parts":[[2018,4,2]],"date-time":"2018-04-02T10:45:14Z","timestamp":1522665914000},"page":"39-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Antiplatelet and anticoagulation regimen in patients with mechanical valve undergoing PCI \u2013 State-of-the-art review"],"prefix":"10.1016","volume":"264","author":[{"given":"Deepakraj","family":"Gajanana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micaela","family":"Iantorno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle D.","family":"Buchanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itsik","family":"Ben-Dor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto D.","family":"Pichard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lowell F.","family":"Satler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Torguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros G.","family":"Okubagzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Waksman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"42","key":"10.1016\/j.ijcard.2018.03.107_bb0005","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1093\/eurheartj\/ehu365","article-title":"The optimal management of anti-thrombotic therapy after valve replacement: certainties and uncertainties","volume":"35","author":"Iung","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2018.03.107_bb0010","series-title":"AHA\/ACC Focused Update of the 2014 AHA\/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","author":"Nishimura","year":"2017"},{"issue":"14","key":"10.1016\/j.ijcard.2018.03.107_bb0015","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1001\/jama.2015.3164","article-title":"Survival and outcomes following bioprosthetic vs mechanical mitral valve replacement in patients aged 50 to 69 years","volume":"313","author":"Chikwe","year":"2015","journal-title":"JAMA"},{"issue":"34","key":"10.1016\/j.ijcard.2018.03.107_bb0020","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1093\/eurheartj\/ehv580","article-title":"Aortic valve replacement with mechanical vs. biological prostheses in patients aged 50\u201369\u202fyears","volume":"37","author":"Glaser","year":"2016","journal-title":"Eur. Heart J."},{"issue":"17","key":"10.1016\/j.ijcard.2018.03.107_bb0025","doi-asserted-by":"crossref","first-page":"1851 LP","DOI":"10.1016\/j.jacc.2016.07.760","article-title":"Efficacy and safety of dual antiplatelet therapy after complex PCI","volume":"68","author":"Giustino","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.ijcard.2018.03.107_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2010.07.038","article-title":"Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary","volume":"160","author":"Mauri","year":"2018","journal-title":"Am. Heart J."},{"issue":"2","key":"10.1016\/j.ijcard.2018.03.107_bb0035","doi-asserted-by":"crossref","first-page":"172 LP","DOI":"10.1016\/j.jcin.2017.08.057","article-title":"Coronary embolus","volume":"11","author":"Raphael","year":"2018","journal-title":"JACC Cardiovasc. Interv."},{"issue":"1","key":"10.1016\/j.ijcard.2018.03.107_bb0040","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ahj.2008.08.023","article-title":"Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic review and meta-analysis of randomized trials","volume":"157","author":"Jolly","year":"2009","journal-title":"Am. Heart J."},{"issue":"4","key":"10.1016\/j.ijcard.2018.03.107_bb0045","first-page":"493","article-title":"Radial versus femoral access for orally anticoagulated patients","volume":"76","author":"Ziakas","year":"2010","journal-title":"Catheter. Cardiovasc. Interv."},{"issue":"4","key":"10.1016\/j.ijcard.2018.03.107_bb0050","doi-asserted-by":"crossref","first-page":"486 LP","DOI":"10.1161\/CIRCULATIONAHA.112.092833","article-title":"Periprocedural bridging management of anticoagulation","volume":"126","author":"Wysokinski","year":"2012","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ijcard.2018.03.107_bb0055","first-page":"407","article-title":"SCAI expert consensus statement: 2016 best practices in the cardiac catheterization laboratory: endorsed by the cardiological society of India, and sociedad Latino Americana de Cardiologia intervencionista; affirmation of value by the Canadian Associatio","volume":"88","author":"Naidu","year":"2016","journal-title":"Catheter. Cardiovasc. Interv."},{"issue":"21","key":"10.1016\/j.ijcard.2018.03.107_bb0060","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes","volume":"355","author":"Stone","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.ijcard.2018.03.107_bb0065","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jama.295.13.joc60034","article-title":"Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial","volume":"295","author":"Kastrati","year":"2006","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.ijcard.2018.03.107_bb0070","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/CIRCULATIONAHA.108.818617","article-title":"Abciximab in patients with acute sT-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading a randomized double-blind trial","volume":"119","author":"Mehilli","year":"2009","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.ijcard.2018.03.107_bb0075","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with Cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.ijcard.2018.03.107_bb0080","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/eurheartj\/ehn099","article-title":"Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment","volume":"29","author":"Karjalainen","year":"2008","journal-title":"Eur. Heart J."},{"issue":"9","key":"10.1016\/j.ijcard.2018.03.107_bb0085","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/ajh.21469","article-title":"Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: treatment","volume":"84","author":"Ageno","year":"2009","journal-title":"Am. J. Hematol."},{"issue":"10","key":"10.1016\/j.ijcard.2018.03.107_bb0090","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1592\/phco.20.15.1159.34585","article-title":"Randomized, placebo-controlled trial of oral Phytonadione for excessive anticoagulation","volume":"20","author":"Patel","year":"2000","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.ijcard.2018.03.107_bb0095","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jcin.2007.12.006","article-title":"Major femoral bleeding complications after percutaneous coronary intervention","volume":"1","author":"Doyle","year":"2008","journal-title":"JACC Cardiovasc. Interv."},{"issue":"6","key":"10.1016\/j.ijcard.2018.03.107_bb0100","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.115.003519","article-title":"Post-discharge bleeding after percutaneous coronary intervention and subsequent mortality and myocardial infarction: insights from the HMO research network-stent registry","volume":"9","author":"Valle","year":"2016","journal-title":"Circ. Cardiovasc. Interv."},{"key":"10.1016\/j.ijcard.2018.03.107_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.carrev.2017.03.027","article-title":"Does the new generation of drug-eluting stents render bare metal stents obsolete?","author":"Buchanan","year":"2017","journal-title":"Cardiovasc. Revasc. Med."},{"issue":"21","key":"10.1016\/j.ijcard.2018.03.107_bb0110","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1056\/NEJMoa1503943","article-title":"Polymer-free drug-coated coronary stents in patients at high bleeding risk","volume":"373","author":"Urban","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.ijcard.2018.03.107_bb0115","doi-asserted-by":"crossref","first-page":"805 LP","DOI":"10.1016\/j.jacc.2014.11.053","article-title":"Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates","volume":"65","author":"Valgimigli","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.ijcard.2018.03.107_bb0120","doi-asserted-by":"crossref","first-page":"496 LP","DOI":"10.1016\/j.jacc.2013.05.022","article-title":"Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction","volume":"62","author":"Palmerini","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"24","key":"10.1016\/j.ijcard.2018.03.107_bb0125","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1056\/NEJMoa1614954","article-title":"Bioresorbable scaffolds versus metallic stents in routine PCI","volume":"376","author":"Wykrzykowska","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.ijcard.2018.03.107_bb0130","article-title":"Duration of dual antiplatelet therapy: a systematic review for the 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Assoc","volume":"134","author":"Bittl","year":"2016","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.ijcard.2018.03.107_bb0135","first-page":"2510","article-title":"Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the optimize randomized trial","volume":"310","author":"Feres","year":"2013","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.ijcard.2018.03.107_bb0140","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jacc.2014.09.008","article-title":"Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy","volume":"64","author":"Colombo","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"8","key":"10.1016\/j.ijcard.2018.03.107_bb0145","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jacc.2014.11.008","article-title":"6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin","volume":"65","author":"Gilard","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"issue":"15","key":"10.1016\/j.ijcard.2018.03.107_bb0150","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jacc.2011.06.049","article-title":"Impact of the everolimus-eluting stent on stent thrombosis","volume":"58","author":"Baber","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9851","key":"10.1016\/j.ijcard.2018.03.107_bb0155","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/S0140-6736(12)61336-1","article-title":"Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial","volume":"380","author":"Camenzind","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ijcard.2018.03.107_bb0160","first-page":"390","article-title":"Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials","volume":"37","author":"Udell","year":"2016","journal-title":"Eur. Heart J."},{"issue":"11","key":"10.1016\/j.ijcard.2018.03.107_bb0165","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.116.004395","article-title":"Antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention","volume":"9","author":"Angiolillo","year":"2016","journal-title":"Circ. Cardiovasc. Interv."},{"issue":"4","key":"10.1016\/j.ijcard.2018.03.107_bb0170","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ahj.2013.07.028","article-title":"Dual antiplatelet therapy versus oral anticoagulation plus dual antiplatelet therapy in patients with atrial fibrillation and low-to-moderate thromboembolic risk undergoing coronary stenting: design of the MUSICA-2 randomized trial","volume":"166","author":"Sambola","year":"2013","journal-title":"Am. Heart J."},{"issue":"16","key":"10.1016\/j.ijcard.2018.03.107_bb0175","first-page":"1433","article-title":"RIsk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation","volume":"170","author":"ML","year":"2010","journal-title":"Arch. Intern. Med."},{"issue":"5","key":"10.1016\/j.ijcard.2018.03.107_bb0180","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","article-title":"Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial","volume":"127","author":"Dans","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.03.107_bb0185","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ijcard.2017.05.119","article-title":"Antithrombotic regimens in patients with atrial fibrillation and coronary artery disease after percutaneous coronary intervention: a focused review","volume":"243","author":"Chang","year":"2017","journal-title":"Int. J. Cardiol."},{"issue":"9872","key":"10.1016\/j.ijcard.2018.03.107_bb0190","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.ijcard.2018.03.107_bb0195","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jacc.2015.02.050","article-title":"Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: The ISAR-TRIPLE trial","volume":"65","author":"Fiedler","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2018.03.107_bb0200","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.ijcard.2018.03.107_bb0205","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.03.107_bb0210","first-page":"1399","article-title":"New England","author":"Sickles","year":"2017","journal-title":"Journal"},{"issue":"14","key":"10.1016\/j.ijcard.2018.03.107_bb0215","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.jcin.2015.08.018","article-title":"Outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention receiving an oral anticoagulant and dual antiplatelet therapy: a comparison of clopidogrel versus prasugrel from the translate-acs study","volume":"8","author":"Jackson","year":"2015","journal-title":"JACC Cardiovasc. Interv."},{"issue":"1","key":"10.1016\/j.ijcard.2018.03.107_bb0220","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.thromres.2014.10.016","article-title":"Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome","volume":"135","author":"Braun","year":"2015","journal-title":"Thromb. Res."},{"issue":"1","key":"10.1016\/j.ijcard.2018.03.107_bb0225","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/clc.22486","article-title":"Ticagrelor in triple antithrombotic therapy: predictors of ischemic and bleeding complications","volume":"39","author":"Fu","year":"2016","journal-title":"Clin. Cardiol."},{"issue":"4","key":"10.1016\/j.ijcard.2018.03.107_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtcvs.2014.01.004","article-title":"Reduced anticoagulation after mechanical aortic valve replacement: interim results from the prospective randomized on-x valve anticoagulation clinical trial randomized food and drug administration investigational device exemption trial","volume":"147","author":"Puskas","year":"2017","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"36","key":"10.1016\/j.ijcard.2018.03.107_bb0235","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","article-title":"ESC\/EACTS guidelines for the management of valvular heart disease","volume":"38","author":"Baumgartner","year":"2017","journal-title":"Eur. Heart J."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016752731737732X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016752731737732X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:39:14Z","timestamp":1759091954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016752731737732X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":47,"alternative-id":["S016752731737732X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2018.03.107","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiplatelet and anticoagulation regimen in patients with mechanical valve undergoing PCI \u2013 State-of-the-art review","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2018.03.107","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}